Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
41 - 50of about 316 News
41 - 50of about 316 News
February 24, 2022
Not intended for U.S. and UK Media
Bayer extends clinical development program for finerenone with Phase II study investigating the l combination therapy with empagliflozin in patients with chronic kidney disease and type 2 diabetes
READ MORE
February 21, 2022
Not intended for U.S. and UK Media
Bayer’s new treatment Kerendia® (finerenone) approved in EU for adult patients with chronic kidney disease associated with type 2 diabetes
READ MORE
February 17, 2022
Not intended for U.S. and UK Media
Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data
READ MORE
February 17, 2022
Not intended for U.S. and UK Media - Data from Phase III ARASENS trial presented at 2022 ASCO GU Cancers Symposium:
Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer
READ MORE
February 16, 2022
Crop Science R&D Pipeline Update 2022
Bayer highlights advancements of agriculture industry’s most prolific R&D pipeline
READ MORE
February 10, 2022
Not intended for U.S. and UK Media
Bayer Receives U.S. FDA Fast Track Designation for asundexian Stroke Program
READ MORE
February 04, 2022
Bayer will discontinue phase II development candidate eliapixant
READ MORE
January 10, 2022
Bayer and Mammoth Biosciences to collaborate on novel gene editing technology
READ MORE
December 21, 2021
Not intended for U.S. and UK Media
U.S. FDA approves Xarelto™ to treat venous thromboembolism (VTE) and to prevent VTE in children
READ MORE
December 17, 2021
Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for finerenone as a new treatment for adult patients with chronic kidney disease associated with type 2 diabetes
READ MORE
41 - 50of about 316 News
41 - 50of about 316 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases
Discover Bayer's Latest Ad-Hoc Releases
read more